Readers should use the section to check current eligibility, pharmacy or provider policies, and safety questions with a licensed professional before acting
Current Status of Compounding of Tirzepatide: With respect to the current status of compounding of tirzepatide, FDA noted that it wished to avoid unnecessary disruption to patient treatment, and outlined the current enforcement policy moving forward: [T]he agency does not intend to take action against compounders for violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) arising from conditions that depend on tirzepatide injection products inclusion on FDAs drug shortage list: For a state-licensed pharmacy under section 503A of the FD&C Act compounding, distributing or dispensing tirzepatide injections within 60 calendar days from todays announcement, until February 18, 2025
Imiquimod 5% Cream Mechanism: Toll-like receptor 7 agonist
Regardless of body composition, choosing the right injection site matters just as much as choosing the right needle
They need to use consistent functional outcome measures, such as timed up-and-go tests or chair-stand tests
